Vasopressin receptor antagonists in the management of acute heart failure

Bibliography

• WEBER KT: Furosemide in the long-term management of heart failure: the good, the bad, and the uncertain. J. Am. Coll. Cardiol. (2004) 44 (6):1308–1310.
   PubMed Web of Science ®Google Scholar
• ANDRONE AS, HRYNIEWICZ K, HUDAIHED A et al: Relation of unrecognized hypervolaemia in chronic heart failure to clinical status, hemodynamics, and patient outcomes. Am. Cardiol (2004) 93(10):1254–1259.
   PubMed Web of Science ®Google Scholar
• TURNER RA, PIERCE JG, VIGNEAUD V: The purification and the amino acid content of vasopressin preparations. J. Biol. Chem. (1951) 191:21–28.
   PubMed Web of Science ®Google Scholar
• GOLDSMITH SR: Vasopressin as vasopressor. Am. J. Med. (1987) 82(6):1213–1219.
   PubMed Web of Science ®Google Scholar
• MICHELL RH, KIRK CJ, BILLAH MM: Hormonal stimulation of phosphatidylinositol breakdown with particular reference to the hepatic effects of vasopressin. Biochem. Soc. Trans. (1979) 7(5):861–865.
   PubMedGoogle Scholar
• THIBONNIER M, AUZAN C, MADHUN Z et al.: Molecular cloning, sequencing, and functional expression of a cDNA encoding the human Via vasopressin receptor. J. Biol. Chem. (1994) 269(5):3304–3310.
   PubMed Web of Science ®Google Scholar
• SUGIMOTO T, SAITO M, MOCHIZUKI S et al.: Molecular cloning and functional expression of a cDNA encoding the human Vib vasopressin receptor. J. Biol. Chem. (1994) 269(43):27088–27092.
   PubMed Web of Science ®Google Scholar
• BIRNBAUMER M, SEIBOLD A, GILBERT S et al: Molecular cloning of the receptor for human antidiuretic hormone. Nature (1992) 357(6376):333–335.
   PubMed Web of Science ®Google Scholar
• CONWAY RS, NATELSON BH, CHEN WH, TING W: Enhanced coronary vasoconstriction in the Syrian myopathic hamster supports the microvascular spasm hypothesis. Cardiovasc. Res. (1994) 28(3)320–324.
   Google Scholar
• WALKER BR, CHILDS ME, ADAMS EM: Direct cardiac effects of vasopressin: role of VI- and V2-vasopressinergic receptors. Am. Physiol. (1988) 255(2 Part 2):H261–H265.
   Google Scholar
• KHAYYAL MA, ENG C, FRANZEN D, BREALL JA, KIRK ES: Effects of vasopressin on the coronary circulation: reserve and regulation during ischemia. Am. Physiol (1985)248(4 Part 2):H516–H522.
   Google Scholar
• NAITOH M, RISVANIS J, BALDING LC, JOHNSTON CI, BURRELL LM: Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V(1a) and V(2) receptor blockade and ACE inhibition. Cardiovasc. Res. (2002) 54(1):51–57.
   PubMed Web of Science ®Google Scholar
• GOLDSMITH SR, FRANCIS GS, COWLEY AW Jr, GOLDENBERG IF, COHN JN: Haemodynamic effects of infused arginine vasopressin in congestive heart failure. J. Am. Coll. Cardiol. (1986) 8(4):779–783.
   PubMed Web of Science ®Google Scholar
• FUKUZAWA J, HANEDA T, KIKUCHI K: Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor. Mol. Cell. Biochem. (1999) 195(1-2):93–98.
   PubMed Web of Science ®Google Scholar
• XU DL, MARTIN PY, OHARA M et al: Upregulation of aquaporin-2 water channel expression in chronic heart failure rat. Clin. Invest. (1997) 99(7):1500–1505.
   Google Scholar
• ISHIKAWA S: Urinary excretion of aquaporin-2 in pathological states of water metabolism. Ann. Med. (2000) 32(2):90–93.
   PubMed Web of Science ®Google Scholar
• FUNAYAMA H, NAKAMURA T, SAITO T et al.: Urinary excretion of aquaporin-2 water channel exaggerated dependent upon vasopressin in congestive heart failure. Kidney Int. (2004) 66(4):1387–1392.
   PubMed Web of Science ®Google Scholar
• MARTIN PY, ABRAHAM WT, LIEMING X et al: Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. I Am. Soc. Nephrol. (1999) 10(10):2165–2170.
   PubMed Web of Science ®Google Scholar
• BURRELL LM, PHILLIPS PA, RISVANIS J et al: Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat. Am. Physiol. (1998)275(1 Part 2):H176–H182.
   Google Scholar
• SCHRIER RW, ABRAHAM WT: Hormones and hemodynamics in heart failure. N Eng]. J. Med. (1999) 341(8):577–585.
   PubMed Web of Science ®Google Scholar
• YAMANE Y: Plasma ADH level in patients with chronic congestive heart failure. fpn Circ. J. (1968) 32(5):745–759.
   PubMedGoogle Scholar
• FRANCIS GS, BENEDICT C, JOHNSTONE DE et al.: Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation (1990) 82(5):1724–1729.
   PubMed Web of Science ®Google Scholar
• GOLDSMITH SR, FRANCIS GS, COWLEY AW Jr, LEVINE TB, COHN JN: Increased plasma arginine vasopressin levels in patients with congestive heart failure. J. Am. Coll. Cardiol. (1983) 1(6):1385–1390.
   PubMed Web of Science ®Google Scholar
• ROULEAU JL, PACKER M, MOYE L et al.: Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J. Am. Coll Cardiol. (1994) 24(3):583–591.
   PubMed Web of Science ®Google Scholar
• SCHRIER RW, BICHET DG: Osmotic and nonosmotic control of vasopressin release and the pathogenesis of impaired water excretion in adrenal, thyroid, and oedematous disorders. J. Lab. Clin. Med. (1981) 98(1):1–15.
   PubMedGoogle Scholar
• ISHIKAWA S, GOLDBERG JP, SCHRIER DM, AISENBREY GA, SCHRIER RW: Interrelationship between subpressor effects of vasopressin and other vasoactive hormones in the rat. Miner. Electrolyte Metab. (1984) 10(3):184–189.
   PubMedGoogle Scholar
• LEVINE TB, FRANCIS GS, GOLDSMITH SR, COHN JN: The neurohumoral and haemodynamic response to orthostatic tilt in patients with congestive heart failure. Circulation (1983) 67(5):1070–1075.
   PubMed Web of Science ®Google Scholar
• LEE WH, PACKER M: Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation (1986) 73(2):257–267.
   PubMed Web of Science ®Google Scholar
• ELLISON DH: The physiologic basis of diuretic synergism: its role in treating diuretic resistance. Ann. Intern. Med. (1991) 114(10):886–894.
   PubMed Web of Science ®Google Scholar
• COOPER HA, DRIES DL, DAVIS CE, SHEN YL, DOMANSKI MJ: Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation (1999) 100(12):1311–1315.
   PubMed Web of Science ®Google Scholar
• LEE CR, PATTERSON JH, GATTIS W: Renal dysfunction is common in patients with heart failure and preserved systolic function: Retrospective analysis of the digitalis investigational group (DIG) trial. Circulation (2003)108(17):484 (Abstract 2220).
   Google Scholar
• TSUTSUI T, TSUTAMOTO T, MAEDA K, KINOSHITA M: Comparison of neurohumoral effects of short-acting and long-acting loop diuretics in patients with chronic congestive heart failure. Cardiovasc. Pharmacol. (2001)A38 (Suppl. 1):581–585.
   Google Scholar
• BRATER DC: Diuretic therapy. N Eng]. I Med. (1998) 339(6):387–395.
   PubMed Web of Science ®Google Scholar
• NICOD P, WAEBER B, BUSSIEN JP et al: Acute haemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure. Am. J. Cardiol (1985) 55(8):1043–1047.
   PubMed Web of Science ®Google Scholar
• UDELSON JE, SMITH WB, HENDRIX GH et al: Acute haemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation (2001) 104(20):2417–2423.
   PubMed Web of Science ®Google Scholar
• BRATER DC, CHENNAVASIN P, SEI WELL R: Furosemide in patients with heart failure: shift in dose-response curves. Clin. Pharmacol. Ther. (1980) 28(2):182–186.
   PubMed Web of Science ®Google Scholar
• VARGO DL, KRAMER WG, BLACK PK et al: Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clia Pharmacol Ther. (1995) 57(6):601–609.
   PubMed Web of Science ®Google Scholar
• LEE CR, WATKINS ML, PATTERSON JH et al: Vasopressin: a new target for the treatment of heart failure. Am. Heart J. (2003) 146(1):9–18.
   PubMed Web of Science ®Google Scholar
• OHNISHI A, ORITA Y, TAKAGI N et al:Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men. Pharmacol Exp. Ther. (1995) 272(2):546–551.
   PubMed Web of Science ®Google Scholar
• HIRANO T, YAMAMURA Y, NAKAMURA S, ONOGAWA T, MORI T: Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J. Pharmacol Exp. Ther. (2000) 292(0:288–294.
   PubMedGoogle Scholar
• NAITOH M, SUZUKI H, MURAKAMI M et al: Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am. J. Physic] (1994) 267(6 Part 2):H2245–H2254.
   Google Scholar
• GHEORGHIADE M, GATTIS WA, O'CONNOR CM et al: Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. IA/VIA (2004) 291(16):1963–1971.
   Web of Science ®Google Scholar
• GHEORGHIADE M, NIAZI I, OUYANG J et al.: Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation (2003) 107(20:2690–2696.
   PubMedGoogle Scholar
• UDELSON JE: Vasopressin receptor blockade in patients with congestive heart failure: results from a placebo controlled, randomized study comparing the effects of tolvaptan, furosimide, and their combination. J. Am. Coll. Cardiol. (2002) 39\(Suppl. 5) (Abstract).
   Google Scholar
• YATSU T, TOMURA Y, TAHARA A et al: Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin VIA and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure. Eur. Pharmacol (1999) 376(3):239–246.
   PubMed Web of Science ®Google Scholar
• WADA K, FUJIMORI A, MATSUKAWA U et al.: Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure. Eur. Pharmacol (2005) 507(1-3):145–151.
   PubMed Web of Science ®Google Scholar
• TONKON: Interaction between furosemide and oral conivaptan in patients with heart failure. Eur. Heart J. (1999) (Suppl.) (Abstract).
   Google Scholar
• GOLDSMITH SR, FRANCIS GS, COWLEY AW Jr.: Arginine vasopressin and the renal response to water loading in congestive heart failure. Am. .1 Cardiol (1986) 58(3):295–299.
   Google Scholar
• ECELBARGER CA, CHOU CL, LEE AJ et al.: Escape from vasopressin-induced antidiuresis: role of vasopressin resistance of the collecting duct. Am. J. Physic] (1998) 274(6 Part 2):F1161–F1166.
   Google Scholar
• RUSSELL SD, SELARU P, PYNE DA et al.: Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial. Am. Heart J. (2003) 145(1):179–186.
   PubMed Web of Science ®Google Scholar
• FONAROW GC, ADAMS KF Jr, ABRAHAM WT, YANCY CW, BOSCARDIN WJ: Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA (2005) 293(5)572–580.
   Google Scholar
• FRANCIS GS, TANG WH: Vasopressin receptor antagonists: will the Vaptans' fulfill their promise?JAMA (2004) 291(16):2017–2018.
   PubMed Web of Science ®Google Scholar